

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2008; month=6; day=19; hr=18; min=52; sec=14; ms=680;]

=====

Application No: 10511101 Version No: 1.0

Input Set:

Output Set:

Started: 2008-05-29 16:33:21.127
Finished: 2008-05-29 16:33:21.947
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 820 ms
Total Warnings: 11
Total Errors: 0
No. of SeqIDs Defined: 11
Actual SeqID Count: 11

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)

SEQUENCE LISTING

<110> KOGANTY, Rao R.
JIANG, Zi-Hua
YALAMATI, Damayanthi
GANDHI, Sham
BUDZYNSKI, Wladyslaw
KRANTZ, Mark J.
LONGENECKER, Michael B.

<120> SYNTHETIC GLYCO-LIPO-PEPTIDES AS VACCINES

<130> KOGANTY4APCT

<140> 10511101
<141> 2008-05-29

<150> PCT/US03/10750
<151> 2003-04-09

<150> 60/372,105
<151> 2000-04-15

<150> 60/377,595
<151> 2002-05-06

<160> 11

<170> PatentIn version 3.2

<210> 1
<211> 20
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 1

Tyr Ala Phe Lys Tyr Ala Arg His Ala Asn Val Gly Arg Asn Ala Phe
1 5 10 15

Glu Leu Phe Leu
20

<210> 2
<211> 43
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 2

Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro
1 5 10 15

Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser
20 25 30

Thr Ala Pro Pro Ala His Gly Val Ser Ser Leu
35 40

<210> 3
<211> 12
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 3

Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro
1 5 10

<210> 4
<211> 10
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 4

Glu Ala Glu Glu Ala Ala Arg Leu Gln Ala
1 5 10

<210> 5
<211> 20
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (9)...(9)
<223> Xaa is Pro, Ala, Gln or Thr.

<220>
<221> misc_feature

<222> (18)..(18)
<223> Xaa is Asp or Glu.

<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa is Thr or Ser.

<400> 5

Pro Ala Pro Gly Ser Thr Ala Pro Xaa Ala His Gly Val Thr Ser Ala
1 5 10 15

Pro Xaa Xaa Arg
20

<210> 6
<211> 12
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 6

Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr
1 5 10

<210> 7
<211> 9
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 7

Thr Leu Ala Pro Ala Thr Glu Pro Ala
1 5

<210> 8
<211> 9
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 8

Ala Leu Gly Ser Thr Ala Pro Pro Val

<210> 9
<211> 9
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 9

Phe Leu Ser Phe His Ile Ser Asn Leu
1 5

<210> 10
<211> 20
<212> PRT
<213> Artificial

<220>
<223> synthetic

<400> 10

Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala
1 5 10 15

Pro Pro Ala His
20

<210> 11
<211> 27
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (26)..(26)
<223> Is modified by a Palmitoyl group.

<400> 11

Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg
1 5 10 15

Pro Ala Pro Gly Ser Thr Ala Pro Pro Lys Gly
20 25

